Trial Profile
A Pilot Study of Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary)
- Indications Pancytopenia; Thrombocytopenia
- Focus Therapeutic Use
- 12 Dec 2023 Trial design, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 30 Oct 2023 Planned End Date changed from 30 Apr 2024 to 31 Aug 2025.
- 30 Oct 2023 Planned primary completion date changed from 30 Apr 2024 to 31 Aug 2025.